Allosteric inhibition of tRNA synthetase Gln4 by N-pyrimidinyl-β-thiophenylacrylamides exerts highly selective antifungal activity

By sjmartinez • February 26, 2024

Puumala E, Sychantha D, Lach E, Reeves S, Nabeela S, Fogal M, Nigam A, Johnson JW, Aspuru-Guzik A, Shapiro RS, Uppuluri P, Kalyaanamoorthy S, Magolan J, Whitesell L, Robbins N, Wright GD, Cowen LE. Allosteric inhibition of tRNA synthetase Gln4 by N-pyrimidinyl-β-thiophenylacrylamides exerts highly selective antifungal activity. Cell Chem Biol. 2024 Feb 20:S2451-9456(24)00046-1. doi: 10.1016/j.chembiol.2024.01.010. Epub ahead of print. PMID: 38402621.

Tags: antifungal, Candida, fungal pathogens, Gln4, glutaminyl-tRNA synthetase, Infectious Diseases, Publications, translation inhibitor

Related Posts

Integration of HIV pre-exposure prophylaxis (PrEP) services for pregnant and breastfeeding women in eight primary care clinics: results of an implementation science study

Nelson A, Bheemraj K, Dean SS, de Voux A, Hlatshwayo L, Mvududu R, Berkowitz N, Neumuller C, Jacobs S, Fourie S, Coates T, Gail-Bekker L,[...]

How I Do It: Managing Cavitary Coccidioidomycosis Expert Opinions for Improving Patient Outcomes

Donovan FM, Thompson GR 3rd, Blair JE, Johnson RH, Malo J, Albasha W, Worrell SG, Beamer SE, Yaddanapudi K, Galgiani JN, Ampel NM. How I[...]

Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial

Edupuganti S, Hurt CB, Stephenson KE, Huang Y, Paez CA, Yu C, Yen C, Hanscom B, He Z, Miner MD, Gamble T, Heptinstall J, Seaton[...]